Chutima KunacheewaRobert Z. OrlowskiUniversity of Texas MD Anderson Cancer CenterFaculty of Medicine, Siriraj Hospital, Mahidol University2020-01-272020-01-272019-01-27Annual Review of Medicine. Vol.70, (2019), 521-5471545326X006642192-s2.0-85060643542https://repository.li.mahidol.ac.th/handle/20.500.14594/50284© 2019 by Annual Reviews. Multiple myeloma is diagnosed in over 100,000 patients each year worldwide, has an increasing incidence and prevalence in many regions, and follows a relapsing course, making it a significant and growing healthcare challenge. Recent basic, translational, and clinical studies have expanded our therapeutic armamentarium, which now consists of alkylating agents, corticosteroids, deacetylase inhibitors, immunomodulatory agents, monoclonal antibodies, and proteasome inhibitors. New drugs in these categories, and additional agents, including both small and large molecules, as well as cellular therapies, are under development that promise to further expand our capabilities and bring us closer to the cure of this plasma cell dyscrasia.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyArticleSCOPUS10.1146/annurev-med-112017-091045